A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Hereditary Angioedema Types I and II
Interventions
BIOLOGICAL

Low-volume C1-esterase inhibitor

BIOLOGICAL

Higher-volume C1-esterase inhibitor

BIOLOGICAL

Low-volume placebo

BIOLOGICAL

Higher-volume placebo

Trial Locations (39)

1125

Study Site, Budapest

2560

Study Site, Campbelltown

17033

Study Site, Hershey

20815

Study Site, Chevy Chase

23298

Study Site, Richmond

23452

Study Site, Virginia Beach

28007

Study Site, Madrid

28046

Study Site, Madrid

30460

Study Site, Pilsen

35209

Study Site, Birmingham

43235

Study Site, Columbus

43617

Study Site, Toledo

46026

Study Site, Valencia

50005

Study Site, Hradec Králové

52621

Study Site, Tel Litwinsky

64239

Study Site, Tel Aviv

74136

Study Site, Tulsa

75231

Study Site, Dallas

80907

Study Site, Colorado Springs

85251

Study Site, Scottsdale

90146

Study Site, Palermo

90201

Study Site, Bell Gardens

92093

Study Site, La Jolla

92868

Study Site, Orange

94598

Study Site, Walnut Creek

95123

Study Site, Catania

97035

Study Site, Lake Oswego

99204

Study Site, Spokane

400139

Study Site, Cluj-Napoca

540103

Study Site, Mures

02114

Study Site, Boston

45267-0563

Study Site, Cincinnati

L8N 3Z5

Study Site, Hamilton

K1Y 4G2

Study Site, Ottawa

M4V 1R2

Study Site, Toronto

G1V 4M6

Study Site, Québec

08035

Study Site, Barcelona

BN2 5BE

Study Site, Brighton

E1 2ES

Study Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT01912456 - A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema | Biotech Hunter | Biotech Hunter